0000000000553729

AUTHOR

Peter Robert Galle

showing 3 related works from this author

Susceptibility to collagen-induced arthritis is modulated by TGFβ responsiveness of T cells

2004

The objective of our study was to determine the regulatory effects that endogenous transforming growth factor beta (TGFbeta) exerts on T cells in the pathogenesis of collagen-induced arthritis (CIA). CIA was induced in transgenic mice expressing a dominant negative TGFbeta type II receptor in T cells under the control of the human CD2 promoter. Clinical and histological arthritis scores were determined and experiments on disease induction and the healing phase of disease were performed. The proliferation and cytokine production of draining lymph node cells in vitro were analyzed. Transgenic mice were more susceptible to induction of CIA. The overall incidence was higher in transgenic mice t…

T-LymphocytesMice Inbred StrainsMice Transgenictransgenic miceTh1 CellsArthritis ExperimentalSeverity of Illness Indexdominant negative TGFβ type II receptorArthritis RheumatoidMiceMice Inbred DBATransforming Growth Factor betaAnimalsCytokinesCattleDisease SusceptibilityLymph NodesCollagen Type IICells CulturedCrosses GeneticResearch ArticleIFNγCell ProliferationArthritis Research & Therapy
researchProduct

Supp_1 – Supplemental material for Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized control…

2018

Supplemental material, Supp_1 for Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial by Michael Nagel, Julia Schulz, Annett Maderer, Katrin Goepfert, Nadine Gehrke, Thomas Thomaidis, Peter C Thuss-Patience, Salah E Al-Batran, Susanna Hegewisch-Becker, Peter Grimminger, Peter Robert Galle, Markus Möhler and Jörn Markus Schattenberg in Tumor Biology

FOS: Clinical medicineCell Biology111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct